U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545317) titled 'Real-World Study of IL-23 Inhibitors in Active Crohn's Disease' on April 15.
Brief Summary: The goal of this observational study is to learn about the effectiveness and safety of IL-23 inhibitors in adults with active Crohn's disease in real-world clinical practice. The main questions it aims to answer are:
* What proportion of participants achieve clinical remission at Week 12 after starting treatment with an IL-23 inhibitor?
* What are the clinical, endoscopic, biomarker, imaging, and safety outcomes during induction and maintenance treatment?
This is not a head-to-head randomized study. Treatments are selected by treating phy...